StockData
SI-BONE, Inc. logo

SI-BONE, Inc. (SIBN) stock analysis

SIBNNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3044% above fair value
$23.16−0.25 (-1.07%)

Close on Nov 17, 2026Market cap $1.04BP/E –Yield 0.00%

StockData Score

Prices as of Nov 16, 2026How the score works

Value0Growth4Performance3Health4Dividend0

Mixed11 of 30 checks passed

Si-Bone passes 11 of the 30 checks behind our score; 11 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
4/6
Past performance
3/6
Financial health
4/6
Dividend
0/6

What stands out

  • Low debt

    Debt is 19.5% of shareholders' equity, under the 40% we consider low.

  • Revenue growing 10%+ a year

    Revenue grew 23.6% a year over the last three fiscal years.

  • Low bankruptcy risk

    The Altman Z-score is 8.47; above 3 is the safe zone and below 1.8 the distress zone.

  • Guidance raised

    Si-Bone raised its Fiscal Year 2026 Revenue outlook on Nov 2, 2026.

What to watch

  • Margin of safety under 20%

    The price is 43.9% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $23.41 is above our fair value estimate of $16.27.

  • Return on equity under 15%

    Return on equity was -8.3% over the last twelve months and averaged -30.3% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -19.6%, below the 10% that usually covers the cost of capital.

Valuation0/6
  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Si-Bone's price-to-book of 5.75 is above the Surgical, Medical, and Dental Instruments and Supplies median of 3.27.

  • Trading above fair value

    The share price of $23.41 is above our fair value estimate of $16.27.

  • Margin of safety under 20%

    The price is 43.9% above fair value, so there is no margin of safety.

Growth4/6
  • Revenue growing 10%+ a year

    Revenue grew 23.6% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 15.3% over the last twelve months; the Surgical, Medical, and Dental Instruments and Supplies median is 10.4%.

  • Guidance raised

    Si-Bone raised its Fiscal Year 2026 Revenue outlook on Nov 2, 2026.

  • Gross margin improving

    Gross margin was 79.5% over the last twelve months, against 79.4% a year earlier.

Past performance3/6
  • Return on equity under 15%

    Return on equity was -8.3% over the last twelve months and averaged -30.3% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -19.6%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Si-Bone's return on equity of -8.3% is above the Surgical, Medical, and Dental Instruments and Supplies median of -35.2%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -6.9% over the last twelve months, against a 5-year average of -35.9%.

  • Net margin above the industry

    Si-Bone's net margin of -6.9% is above the Surgical, Medical, and Dental Instruments and Supplies median of -14.8%.

Financial health4/6
  • Low debt

    Debt is 19.5% of shareholders' equity, under the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 23.3% five years ago to 19.5%.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals 7.0% of total debt; we look for at least 20%.

  • Interest not well covered

    Operating income covers interest expense -7.1 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 9.15 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 8.47; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6
  • No dividend

    Si-Bone has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Our estimate per share

$16.27

The share price is 44% above this estimate.

20%+ below
Near fair value
20%+ above
$23.41Price$16.27Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/B3.8×4.3×3.3×$15.4950%
P/S3.6×4.5×2.6×$17.0550%
Fair value$16.27100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 4.3
  • Surgical, Medical, and Dental Instruments and Supplies median 3.3

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Medium risk

Average value traded per day
$18.38M
Value traded per 1% price move
$7.08M

Downside

Medium risk

Typical loss in a bad month
21.5%
Volatility (annualized)
50%
Sharpe ratio, 1 year
0.62
Beta to the S&P 500 (5Y)
0.29

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2016 to 2025

Gross margin

79.6%−8.3 pts over 5 years

Operating margin

-11.1%+41.4 pts over 5 years

Net margin

-9.4%+50.1 pts over 5 years

See a number that looks wrong?